pharmaceutical manufacturers

Opinion: More industry-stakeholders play blame game for high drug costsOur policy analyst weighs in on a new drug industry PR campaign that attempts to shift the blame for high drug costs.
How the presidential candidates plan to rein in pharma costs
How the presidential candidates plan to rein in pharma costsFind out where each presidential candidate stands on key issues related to pharmaceutical costs.
Managed care pharmacy survey findings 2016To identify the top managed care pharmacy challenges and what your peers are doing about them, Managed Healthcare Executive, in partnership with Access Market Intelligence and the National Institute of Collaborative Healthcare, conducted its first-ever pharmacy survey during the second quarter of 2016.
Can costs be contained?There’s a lot of blame to go around when it comes to why drug costs are rising in dermatology. We’ll let the research do the finger pointing.
Top 4 pharmacy trends healthcare executives should watch
Top 4 pharmacy trends healthcare executives should watchManaged Healthcare Executive conducted its first-ever managed care pharmacy survey during the second quarter of 2016 in partnership with Access Market Intelligence. Here’s a look at some of the key findings, with experts weighing in on the results.
Spike in drug shortages raises alarm
Spike in drug shortages raises alarmDrug shortages take a toll, especially on emergency department patients.
Addressing rising pharma costs: A roundtable discussionAt the AMCP16 conference, Managed Healthcare Executive invited some of the nation’s leading pharmacy and managed care experts to join us to discuss some of the most critical managed care pharmacy challenges facing the industry.
Pharma responds to critics with new drug adsPhRMA ad campaign features new patient and researcher stories.
Top 5 industry challenges of 2016
Top 5 industry challenges of 2016The top 5 industry challenges facing managed care executives, according to the findings of Managed Healthcare Executive's State of the Industry Survey.
Top ways to tap value from specialty drugs for chronic careThe next stage of chronic care management and value-based insurance design for the continuing onslaught of high-priced specialty drugs, including PCSK9 inhibitors.